In a nutshell This phase 1b trial is examining the effectiveness and safety of cibisatamab in combination with atezolizumab (Tecentriq) after treatment with obinutuzumab (Gazyva) in patients with previously treated metastatic colorectal carcinoma (mCRC). The main outcomes to be measured will be side effects and...
Read MorePerformance status-1 – Slightly symptomatic Posts on Medivizor
Looking patients with advanced cancer to test a new immunotherapy combination
In a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...
Read MoreSearching for patients with locally advanced non-small cell lung cancer to test a chemoradiotherapy regimen
In a nutshell This trial is examining the effectiveness and safety of standard chemoradiation vs a PET base chemoradiation combination in patients with non-small cell lung carcinoma (NSCLC). The main outcomes to be measured will be side effects and survival without cancer growing or spreading. The details A treatment option for...
Read MoreSearching for patients with advanced triple negative breast cancer to test this new treatment option
In a nutshell This phase 1/2 trial is examining the effectiveness and safety of KY1044 alone and in combination with atezolizumab (Tecentriq) for patients with advanced cancers who are not suitable for any other treatment or have failed all other treatment options. The main outcomes to be measured will be the occurrence and severity of side effects and...
Read MoreSearching for patients with advanced non-small cell lung cancer to test a new T-cell treatment
In a nutshell This phase 2 trial will investigate the effectiveness of genetically-engineered cell treatment (GECT) in advanced cancer. The main outcome will be the response to treatment. This trial is recruiting at the National Cancer Institute, Maryland, US. The details There are limited treatment options for advanced cancer. One...
Read MoreLooking for patients with non-small cell lung cancer to test a new immunotherapy combination
In a nutshell This phase 2 trial will investigate the safety and effectiveness of different treatment combinations containing durvalumab (Imfinzi) in non-small cell lung cancer (NSCLC). The main outcome will be the objective response rate (ORR). The details Non-small cell lung cancer (NSCLC) is a common form of lung cancer. It is often diagnosed at...
Read MoreLooking for patients with advanced BRAF positive colorectal cancer to test an immunotherapy treatment
In a nutshell This trial is examining the effectiveness and safety of encorafenib (Braftovi), binimetinib (Mektovi) and cetuximab (Erbitux) in patients with advanced colorectal cancer. The main outcome to be measured will be tumor response to the treatment. The details Colorectal cancer is the third most common cancer worldwide. A high number of...
Read MoreSearching for patients with recurrent multiple myeloma to test daratumumab
In a nutshell This phase 2 trial is evaluating how well daratumumab (Darzalex) works in treating patients with multiple myeloma (MM) that has come back after a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This trial is recruiting in Houston,...
Read MoreSearching for patients with non-small cell lung cancer suitable for surgery to test durvalumab with chemotherapy
In a nutshell This phase 3 trial is examining the effectiveness of durvalumab (Imfinzi) combined with chemotherapy vs chemotherapy alone for stage II and III non-small cell lung cancer (NSCLC) before surgery. The main outcome to be measured will be the major pathological response (mPR; 10 percent or fewer alive cancer cells...
Read MoreSearching for patients with colorectal cancer to test this new treatment combination
In a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for advanced or unresponsive colorectal cancer (CRC) and other solid tumors. The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...
Read MoreSearching for patients with triple negative breast cancer to test this new treatment combination
In a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for triple negative breast cancer (TNBC) and other solid tumors. The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...
Read MoreSearching for patients with non-small cell lung cancer to trial a new targeted therapy drug
In a nutshell This phase 3 trial will investigate the safety and effectiveness of osimertinib (Tagrisso) after chemoradiation (CR) in non-small cell lung cancer (NSCLC). The main outcome will be progression-free survival (PFS; survival without cancer growing or spreading). The details Non-small cell lung cancer (NSCLC) is the most...
Read More
